492,394 Shares in Advaxis (ADXS) Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC acquired a new stake in Advaxis (NASDAQ:ADXS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 492,394 shares of the biotechnology company’s stock, valued at approximately $1,398,000. Renaissance Technologies LLC owned 1.19% of Advaxis as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Bank of Montreal Can increased its stake in Advaxis by 16,465.9% in the 4th quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock valued at $1,230,000 after buying an additional 430,583 shares during the period. Franklin Street Advisors Inc. NC increased its stake in Advaxis by 117.1% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 129,800 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 70,000 shares during the period. Cutler Capital Management LLC increased its stake in Advaxis by 51.8% in the 4th quarter. Cutler Capital Management LLC now owns 75,876 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 25,876 shares during the period. Capital Analysts LLC increased its stake in Advaxis by 2,214.3% in the 4th quarter. Capital Analysts LLC now owns 69,428 shares of the biotechnology company’s stock valued at $3,962,000 after buying an additional 66,428 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Advaxis by 39.9% in the 4th quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 18,892 shares during the period. 28.27% of the stock is currently owned by institutional investors.

Shares of Advaxis opened at $1.77 on Friday, according to MarketBeat Ratings. Advaxis has a one year low of $1.91 and a one year high of $1.97.

Advaxis (NASDAQ:ADXS) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.06. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. The company had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million. equities analysts expect that Advaxis will post -1.73 earnings per share for the current year.

Several equities research analysts have commented on ADXS shares. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Advaxis in a research report on Tuesday, April 17th. ValuEngine upgraded shares of Advaxis from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Cantor Fitzgerald decreased their target price on shares of Advaxis from $19.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 13th.

Advaxis Profile

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply